Ospedale Di Sassuolo S.p.A.
- Address
- lock Available on a paid plan
Female Urogenital & Pregnancy Research
The oncology team is studying endometrial cancer to determine whether adding a new immunotherapy improves survival, while also evaluating maintenance strategies for BRCA wild‑type ovarian cancer after platinum response. A separate trial focuses on women with premature rupture of membranes to see if early active management reduces neonatal respiratory support.
- Immunotherapy plus chemotherapy for advanced endometrial cancer
- Olaparib maintenance in BRCA‑wild type ovarian and peritoneal cancers
- Early induction versus expectant care for PROM in pregnancy
These studies aim to test new therapeutic combinations, improve post‑treatment maintenance, and enhance perinatal outcomes for patients facing gynecologic malignancies and pregnancy complications.
Hematologic & Lymphoid Oncology
Researchers are comparing a modern tyrosine‑kinase inhibitor with a classic agent in newly diagnosed chronic myeloid leukemia to find the optimal frontline approach. In elderly patients with diffuse large B‑cell lymphoma and high‑grade follicular lymphoma, a pre‑phase regimen with vitamin D supplementation is being tested for better tolerance. Another study examines a reduced‑cycle chemotherapy strategy for high‑burden follicular lymphoma to maintain efficacy while lowering toxicity.
- Frontline nilotinib versus imatinib in chronic phase CML
- Prednisone ± vitamin D prephase before immunochemotherapy for elderly DLBCL
- Shortened chemotherapy combined with immunotherapy for high‑tumor‑burden FL
The goal across these trials is to refine treatment effectiveness, reduce side‑effects, and personalize therapy based on disease biology and patient age.
Solid Tumor Clinical Research
A trial in metastatic colorectal cancer evaluates first‑line FOLFIRI paired with either bevacizumab or cetuximab, guided by tissue and liquid‑biopsy RAS/BRAF status. Additional investigations focus on biomarker‑driven maintenance with olaparib in ovarian cancer and on novel combinations for advanced solid tumors.
- RAS/BRAF‑guided first‑line therapy selection in mCRC
- Olaparib maintenance after platinum response in ovarian cancer
- Combination strategies to delay recurrence in high‑grade solid tumors
These projects aim to improve progression‑free survival, personalize treatment based on molecular profiles, and explore new maintenance options for patients with advanced malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fondazione Italiana Linfomi Ets4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale Di Sassuolo S.p.A.
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase III multicenter, double-blind, randomized, placebo-controlled, parallel-group trial of the efficacy of citicoline eyedrops 2% on visual field preservation in patients with open angle glaucoma | Omikron Italia S.r.l. | Phase III | Recruiting | Nov 2023 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Obinutuzumab | 2 | Unknown | 2021-12-01 | 2023-12-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.